Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective

BACKGROUND: Cost-effectiveness of atezolizumab, as a treatment for advanced non-small-cell lung cancer (NSCLC) patients who cannot receive a platinum-containing regimen,was still unknown. Our objective was to evaluate the cost-effectiveness of atezolizumab vs. chemotherapy in this indication from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yunlin, Zhao, Mingye, Xi, Jiayi, Li, Jiaqi, Tang, Wenxi, Zheng, Xueping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570614/
https://www.ncbi.nlm.nih.gov/pubmed/37841712
http://dx.doi.org/10.3389/fpubh.2023.1282374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570614/
https://www.ncbi.nlm.nih.gov/pubmed/37841712
http://dx.doi.org/10.3389/fpubh.2023.1282374

Ejemplares similares